( March 5, 2025, 12:36 PM EST) -- WASHINGTON, D.C. — A Federal Circuit U.S. Court of Appeals panel on March 4 affirmed a decision from the U.S. Patent Trial and Appeal Board (PTAB), agreeing that an appellant stem cell research company failed to show that a respondent competitor’s patent was invalid as obvious or anticipated by prior art references; the panel held that the PTAB did not err in its construction of multiple claim phrases....